Overview

Study to Evaluate the Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease Resulting From Nuclear DNA Mutations (nPMD)

Status:
Not yet recruiting
Trial end date:
2024-06-01
Target enrollment:
Participant gender:
Summary
SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD).
Phase:
Phase 3
Details
Lead Sponsor:
Stealth BioTherapeutics Inc.